Corey Langer
MD, FACP
Director of Thoracic Oncology
Abramson Cancer Center, Hospital of the University of Pennsylvania

Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center. Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987.
Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008. He moved to the University of Pennsylvania in 2008, where he helps lead clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC.
Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG. Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). Since 2016, he has been Editor-in-Chief of the International Lung Cancer News (ILCN) under the aegis of the IASLC.
He has authored or co-authored over 220 peer-reviewed papers in thoracic oncology.

Sessions

Register
General Session

Case-Based Treatment Strategies in Lung Cancers

Saturday, March 14, 2026
11:10 AM - 11:55 AM
General Session

Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy

Saturday, March 14, 2026
4:25 PM - 5:10 PM
General Session

Systemic Therapy Alone

Sunday, March 15, 2026
11:10 AM - 11:30 AM
General Session

Management of Oligo-Remnant Metastatic Lung Cancer: Systemic Therapy Alone vs Systemic Therapy Plus Local Ablation

Sunday, March 15, 2026
11:10 AM - 11:55 AM
General Session

Treatment After Progression on Chemoimmunotherapy in Lung Cancer: Continuing Standard Cytotoxic Therapy vs Transitioning to Alternative Approaches

Sunday, March 15, 2026
2:55 PM - 3:40 PM
General Session

Resectable Lung Cancer: Neoadjuvant Only vs Perioperative Therapy

Saturday, September 26, 2026
10:05 AM - 10:50 AM
General Session

First-Line Strategies in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: Monotherapy Approaches vs Combination Approaches

Saturday, September 26, 2026
3:30 PM - 4:15 PM
General Session

Management of Oligo-Remnant Metastatic Lung Cancer: Systemic Therapy Alone vs Systemic Therapy Plus Local Ablation

Sunday, September 27, 2026
10:05 AM - 10:50 AM
General Session

Treatment After Progression on Chemoimmunotherapy in Non-Small Cell Lung Cancer: Continuing Standard Cytotoxic Therapy vs Transitioning to Alternative Approaches

Sunday, September 27, 2026
3:30 PM - 4:15 PM
Back to top